Companies: 10,795·Total market cap: $144.5T
Aura Biosciences, Inc.

Aura Biosciences, Inc.

AURANASDAQHealthcare● Active
$6.50
$-0.13(-2.02%)
Market Cap$417041745
P/E Ratio
52W High$9.535
52W Low$4.73
SEC Filings

Aura Biosciences, Inc. (AURA) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001501796 · AURA · NASDAQ · as of Jun 8, 2026

Filing snapshot

346
Total Filings
4
Latest Form
2026-05-19
Most Recent
2021
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001501796 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-30
Fiscal Year End
Mar 30, 2026
Accession No.
0001193125-26-130401
Primary Document
aura-20251231.htm
Source: data.sec.gov · CIK 0001501796 · Accession 0001193125-26-130401

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-11
8-KCurrent Report
8-K
2026-05-11Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
S-8Employee Stock Plan Registration
S-8
2026-05-19
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-05-12
View
10-QQuarterly Report
10-Q
2026-05-11
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-05-11
View
8-KCurrent Report
8-K
2026-05-11
View
3Initial Statement of Beneficial Ownership
3
2026-05-07
View
8-KCurrent Report
8-K
2026-05-05
View
424B5424B5
424B5
2026-05-05
View
8-KCurrent Report
8-K
2026-05-04
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-05-04
View
S-3MEFS-3MEF
S-3MEF
2026-05-04
View
424B5424B5
424B5
2026-05-04
View
8-KCurrent Report
8-K
2026-05-04
View
ARSARS
ARS
2026-04-20
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-20
View
Showing 1–15 of 203 filingsForm 4 / 144 hidden· 346 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001501796  |  Exchange: NASDAQ · Healthcare

Aura Biosciences, Inc. (NASDAQ: AURA) has submitted 346 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2021. As a Healthcare sector company with CIK 0001501796, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Aura Biosciences, Inc.'s most comprehensive regulatory disclosure. The most recent Aura Biosciences, Inc. 10-K was filed on 2026-03-30 for fiscal year ending 2026. Historical AURA 10-K annual reports are available from 2010 through 2026.

Investors researching Aura Biosciences, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

AURA SEC Filings · 8 questions

Aura Biosciences, Inc. (AURA) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 346 filings and access original documents at no cost. Aura Biosciences, Inc.'s CIK is 0001501796.

AURA SEC filingsAura Biosciences, Inc. SEC documentsfind AURA 10-K